AERI - Aerie Pharmaceuticals, Inc.
| Previous close | 14.46 |
| Open | 14.75 |
| Bid | 13.50 x 800 |
| Ask | 14.69 x 800 |
| Day's range | 13.81 - 14.97 |
| 52-week range | 10.80 - 26.34 |
| Volume | 798,415 |
| Avg. volume | 942,569 |
| Market cap | 649.162M |
| Beta (5Y monthly) | 1.05 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -4.41 |
| Earnings date | 06 May 2020 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 32.33 |
- Motley Fool
Is Aerie Pharmaceuticals a Buy?
Wall Street has given the eye-care specialist the cold shoulder in 2020. Is that an opportunity for individual investors?
- Business Wire
Aerie Pharmaceuticals Appoints Peter J. McDonnell, M.D., to the Company’s Board of Directors
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, dry eye, retinal diseases and potentially other diseases of the eye, today announced that Peter J. McDonnell, M.D., has been appointed to the Company’s Board of Directors and will also be a member of both the Nominating and Corporate Governance and Compensation Committees of the Board.
- Zacks
Aerie (AERI) Up 1.9% Since Last Earnings Report: Can It Continue?
Aerie (AERI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Motley Fool
Aerie Pharmaceuticals Inc (AERI) Q1 2020 Earnings Call Transcript
AERI earnings call for the period ending March 31, 2020.
- Zacks
Aerie Pharmaceuticals (AERI) Reports Q1 Loss, Lags Revenue Estimates
Aerie (AERI) delivered earnings and revenue surprises of -12.00% and -3.32%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
- Business Wire
Aerie Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Business Update
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, dry eye, retinal diseases and potentially other diseases of the eye, today reported financial results for the first quarter ended March 31, 2020 and provided a general business update, including the impact of the COVID-19 pandemic on company operations.
- Business Wire
Aerie Pharmaceuticals to Present at the Bank of America Securities 2020 Healthcare Conference
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, dry eye, retinal diseases and other diseases of the eye today announced that Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer, will present in a fireside discussion at the Bank of America Securities 2020 Healthcare Conference on Tuesday, May 12, 2020 at 8:20 a.m. Eastern Time. Dr. Anido will provide an Aerie overview and business update.
- Business Wire
Aerie Pharmaceuticals to Announce First Quarter 2020 Financial Results and Host Conference Call on Wednesday, May 6, 2020
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, dry eye, retinal diseases and other diseases of the eye announced today that its first quarter 2020 financial results will be released after the market closes on Wednesday, May 6, 2020. Following the release, the Company will host a live conference call and webcast at 5:00 p.m. Eastern Time to discuss the Company’s financial results and provide a general business update.
- Business Wire
Aerie Pharmaceuticals Provides 2020 Company and Guidance Update Associated with COVID-19
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, dry eye, retinal diseases and other diseases of the eye today provided a business update associated with the impact of the global Coronavirus disease (COVID-19) pandemic on Company operations.
- Business Wire
Aerie Pharmaceuticals to Present at the Needham Virtual Healthcare Conference
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, dry eye, retinal diseases and other diseases of the eye today announced that Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer, will present in a fireside discussion at the Needham Virtual Healthcare Conference on Tuesday, April 14, 2020 at 12:50 p.m. Eastern Time. Dr. Anido will provide an Aerie overview and business update.
- Simply Wall St.
Aerie Pharmaceuticals, Inc. Just Released Its Yearly Results And Analysts Are Updating Their Estimates
A week ago, Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) came out with a strong set of full-year numbers that could...
- Simply Wall St.
Aerie Pharmaceuticals, Inc.'s (NASDAQ:AERI) Path To Profitability
Aerie Pharmaceuticals, Inc.'s (NASDAQ:AERI): Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company, focuses...
- Simply Wall St.
Does Aerie Pharmaceuticals (NASDAQ:AERI) Have A Healthy Balance Sheet?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...
- Zacks
Aerie's (AERI) Application for Roclanda Accepted in Europe
European authorities accept Aerie's (AERI) filing for its second ophthalmology drug, Roclanda.
- Zacks
Aerie (AERI) Up 4.7% Since Last Earnings Report: Can It Continue?
Aerie (AERI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Simply Wall St.
Did Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Insiders Buy Up More Shares?
It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...
- Zacks
Aerie to Acquire Dry Eye Disease-Focused Pharma Avizorex
Aerie (AERI) will acquire Spanish ophthalmic pharmaceutical company, Avizorex Pharma, to add a mid-stage dry eye disease candidate to its pipeline.
- Zacks
Aerie (AERI) Q3 Loss Wider, Sales Beat, Guidance Slashed
Aerie (AERI) posts a wider-than-expected Q3 loss and lowers guidance.
- Zacks
Aerie Pharmaceuticals (AERI) Reports Q3 Loss, Tops Revenue Estimates
Aerie (AERI) delivered earnings and revenue surprises of -2.38% and 5.45%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
Aerie Pharmaceuticals (AERI) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Aerie (AERI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Simply Wall St.
Imagine Owning Aerie Pharmaceuticals (NASDAQ:AERI) While The Price Tanked 62%
The nature of investing is that you win some, and you lose some. And there's no doubt that Aerie Pharmaceuticals, Inc...
- Zacks
Aerie Secures Positive CHMP Opinion for Eye Drug Rhokiinsa
The CHMP recommends Aerie's (AERI) marketing application for Rhokiinsa to reduce elevated intraocular pressure in adult patients with open-angle glaucoma or ocular hypertension.
- Simply Wall St.
Will Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Need To Raise More Money?
As the US$994m market cap Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) released another year of negative earnings...
